RSS Channels Index
Combination of Drugs Produces Dramatic Tumor Responses in Advanced Melanoma Patients
The combination of the immunotherapy drug ipilimumab and the investigational antibody drug nivolumab led to long-lasting tumor shrinkage in more than half of patients with metastatic melanoma, according to new research from Memorial Sloan-Kettering...
5/31/2013 10:30 AM EDT
New Therapy Shown To Improve Progression-Free Survival and Shrink Tumors in Rare Cancer for the First Time
The experimental drug selumetinib is the first targeted therapy to demonstrate significant clinical benefit for patients with metastatic uveal melanoma, according to new Memorial Sloan-Kettering Cancer Center research presented on Saturday, June 1,...
5/31/2013 10:30 AM EDT
Large Genomic Study Identifies Endometrial Cancer Subtypes, Treatment Opportunities
An analysis of endometrial cancers reveals genetic information that should improve diagnosis and guide treatments for women with an aggressive form of the disease.
5/1/2013 1:00 PM EDT
New Monoclonal Antibody Developed That Can Target Proteins Inside Cancer Cells
Scientists from Memorial Sloan-Kettering Cancer Center and Eureka Therapeutics have collaborated to create a unique monoclonal antibody that can effectively reach inside a cancer cell.
3/13/2013 2:00 PM EDT
Memorial Sloan-Kettering Appoints Avice Meehan as Vice President of Communications and Chief Communications Officer
Memorial Sloan-Kettering Cancer Center has announced the appointment of Avice Meehan to Vice President of Communications and Chief Communications Officer.
3/12/2013 12:00 PM EDT
Memorial Sloan-Kettering Announces New Appointments
Memorial Sloan-Kettering Cancer Center announces new appointments.
3/5/2013 9:45 AM EST
Physician-Scientist Charles Sawyers Awarded Breakthrough Prize in Life Sciences
Charles L. Sawyers, Chair of Memorial Sloan-Kettering’s Human Oncology and Pathogenesis Program (HOPP), was awarded the Breakthrough Prize in Life Sciences today.
2/20/2013 4:35 PM EST
Drug Shown to Reverse Radioiodine Resistance in Some Advanced Thyroid Cancers
Memorial Sloan-Kettering Cancer Center researchers have found that the investigational drug selumetinib shuts down the signaling of genetic mutations that prevent some patients’ thyroid cancer tumors from absorbing radioiodine, the most effective...
2/13/2013 5:00 PM EST
Ovarian Cancer Expert Available to Comment on New Study Reported in Today's New York Times
3/12/2013 6:00 PM EDT
Phase III Crizotinib Data at ESMO: Memorial Sloan-Kettering Expert Available for Comment
9/28/2012 12:40 PM EDT
